BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » iPS Cells » Page 46

Notch Therapeutics Closes $85M Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies

By Leave a Comment

— Financing supports advancement of initial T cell-based pipeline for cancer and
expanded development of Engineered Thymic Niche (ETN) platform for multiple immune cell types—

VANCOUVER, British Columbia, February 10, 2021— Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. [Read more…]

Implant Therapeutics To Engineer iPSC-MSC Cells Containing panCELLa’s Technologies

By Leave a Comment

TORONTO, Jan. 8, 2021– panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics.

Implant Therapeutics, under the guidance of Dr. Mahendra Rao, is engineering iPSC-MSC cells containing panCELLa’s FailSafe™ and induced Allogeneic Cell Tolerance (iACT Stealth Cell™) technologies.  These iPSC MSC cells are hypo-immunogenic and are an ideal choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles. [Read more…]

Evotec Achieves Milestone within iPSC-Based Neuroscience Partnership with BMS

By Leave a Comment

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry.

HAMBURG, GERMANY / January 5, 2021 — Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced that the Company has received a US $6 million payment from Bristol Myers Squibb Company (NYSE: BMY) within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. [Read more…]

Spinogenix Secures DOD Grant To Study Lead Compound in hiPSCs from Patients with ALS

By Leave a Comment

Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)

SAN DIEGO, Calif., Jan. 05, 2021 — Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced that it will be collaborating with Dr. Rita Sattler at the Barrow Neurological Institute and Dr. Justin Ichida at the USC Keck School of Medicine on a grant awarded from the U.S. Department of Defense’s (“DOD”) Congressionally Directed Medical Research Programs (“CDMRP”) to evaluate its lead development candidate in ALS. [Read more…]

The State of iPS Cell Clinical Trials in 2021

By 1 Comment

Numerous induced pluripotent stem cell (iPSC) derived therapeutics are now being studied in preclinical and clinical trials to investigate their potential to produce functional cells capable of replacing damaged or dysfunctional tissues.

It is important to note that the early clinical trials of iPSCs—and the majority of them today—do not involve the transplant of iPSCs into humans. Rather, they involve the creation and evaluation of iPSC lines for clinical purposes. Within these trials, iPSC lines are created from specific patient populations to determine if these cell lines could be a good model for a disease of interest. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0